Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIGB-845
- Development stage
- Unknown
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Intranasal, Intravenous, Subcutaneous
01
Overview
CIGB-845 is a neuroprotective and neurorestorative combination therapy consisting of growth hormone-releasing peptide 6 (GHRP-6) and epidermal growth factor (EGF). Developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, it is designed to provide a multi-target approach to central nervous system protection. EGF promotes neurogenesis and remyelination, while GHRP-6 induces the expression of endogenous neuroprotective factors, offering anti-apoptotic and anti-excitotoxic effects. The drug is primarily being advanced for the treatment of ischemic stroke, with preclinical evidence supporting its potential in amyotrophic lateral sclerosis (ALS) and autoimmune encephalitis.
- Other names
- GHRP-6 + EGF
02
Targets
GHSR (Growth hormone secretagogue receptor)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on CIGB-845.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIGB-845.